RxDoctor Payments Data

Marco Paez, MD

Gastroenterology · Corona, CANPI 1902167695

Payments from drug & device makers

$4,809in general payments, 2019–2025

Across 163 payments — averaging $29.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$885
  • Madrigal Pharmaceuticals$692
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$663
  • Johnson & Johnson$343
  • Conmed Corporation$308
  • Pfizer$223
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,68197%
  • Education$1283%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,809 in reported general payments places this provider in the 60th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$68,671
Medicare patients
187
Services billed
448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin14$43,839
LinzessLinaclotide13$14,821
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,606
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl110$1,729
Omeprazole108$1,275
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl81$1,260
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates19$1,177
Lactulose11$401
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl13$216
Famotidine13$199
Pantoprazole Sodium16$148
Dicyclomine Hcl20$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$663$43,83914 claims
AbbVieLinzess$885$14,82113 claims
Braintree Laboratories, Inc.Sutab$41$2,60616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →